(Q36577362)

15 August 2017

1 reference

title

Optimum therapeutic approaches for lupus nephritis: what therapy and for whom? (English)

1 reference

15 August 2017

1 reference

Dimitrios T Boumpas

1

1 reference

15 August 2017

Prodromos Sidiropoulos

series ordinal

2

1 reference

15 August 2017

George Bertsias

series ordinal

3

1 reference

15 August 2017

publication date

1 November 2005

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

22-30

1 reference

https://scigraph.springernature.com/pub.10.1038/ncprheum0016

15 August 2017

exact match

0 references

cites work

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Use of testosterone to prevent cyclophosphamide-induced azoospermia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Preserving ovarian function in patients receiving cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Maintenance therapy for lupus nephritis--something old, something new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Membranous lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

21 January 2018

Lupus nephritis flares

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Rituximab for idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Lupus nephritis: treatment with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0016

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0016

1 reference

Dimensions Publication ID

15 August 2017

1027288478

0 references

1 reference